Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):387-96. doi: 10.1177/039463201002300201.
The potent systemic immunosuppression therapy necessary to sustain a life-saving solid organ transplant is associated with an increased incidence of various infections including human papillomavirus infection and skin cancers in organ transplant recipients. Imiquimod, a topical agent that functions through local induction of a specific anti-viral or anti-tumor immune response, appears to be a promising therapeutic option that could potentially counteract in situ the effects of systemic immunosupression in this vulnerable group. Up-to-date studies using this local immune-response modifier in transplanted patients have yielded reassuring and encouraging results regarding its safety and efficacy in this population. However, in order to establish the use of imiquimod as a standard treatment option for organ transplant recipients, additional research and clinical trials are required.
强效的全身性免疫抑制治疗是维持挽救生命的实体器官移植所必需的，但会增加包括人乳头瘤病毒感染和器官移植受者皮肤癌在内的各种感染的发生率。咪喹莫特是一种局部诱导特定抗病毒或抗肿瘤免疫反应的药物，似乎是一种很有前途的治疗选择，可能会在局部抵消这一脆弱人群的全身性免疫抑制的作用。目前，在移植患者中使用这种局部免疫调节剂的研究已经获得了令人安心和鼓舞的结果，证实了其在该人群中的安全性和有效性。然而，为了将咪喹莫特确立为器官移植受者的标准治疗选择，还需要开展更多的研究和临床试验。
